Sacituzumab govitecan (IMMU-132) 是一种抗体-药物偶联物 (ADC)，靶向Trop-2传递 SN-38。Sacituzumab govitecan 具有抗癌活性。
| 生物活性 | Sacituzumab govitecan (IMMU-132) is anantibody-drug conjugate (ADC)targetingTrop-2for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1]. |
体内研究
(In Vivo) | Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts[1].
|
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Store at 4°C, do not freeze |
m.cnreagent.com